Bank of America Issues Pessimistic Forecast for Danaher (NYSE:DHR) Stock Price

Danaher (NYSE:DHR) had its target price reduced by Bank of America from $230.00 to $220.00 in a report issued on Monday morning,Benzinga reports. They currently have a buy rating on the conglomerate’s stock.

Several other equities research analysts have also commented on DHR. Wells Fargo & Company reduced their price target on shares of Danaher from $210.00 to $205.00 and set an “equal weight” rating for the company in a report on Wednesday, July 23rd. Scotiabank raised shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 price objective for the company in a research note on Friday, July 11th. Royal Bank Of Canada set a $241.00 target price on Danaher in a research report on Tuesday, September 2nd. Robert W. Baird lifted their price target on Danaher from $225.00 to $226.00 and gave the company an “outperform” rating in a report on Friday, July 18th. Finally, Barclays restated an “overweight” rating and set a $225.00 price objective (up from $215.00) on shares of Danaher in a research note on Tuesday, June 24th. Seventeen analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $245.91.

Danaher Trading Down 2.0%

DHR opened at $185.90 on Monday. The company has a quick ratio of 1.22, a current ratio of 1.62 and a debt-to-equity ratio of 0.32. The stock’s fifty day moving average is $199.80 and its two-hundred day moving average is $197.89. The company has a market capitalization of $133.11 billion, a P/E ratio of 39.55, a PEG ratio of 2.70 and a beta of 0.75. Danaher has a 52 week low of $171.00 and a 52 week high of $279.90.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. The business had revenue of $5.94 billion for the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a return on equity of 10.70% and a net margin of 14.21%.The business’s revenue was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.72 EPS. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Analysts forecast that Danaher will post 7.63 earnings per share for the current year.

Danaher Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Friday, September 26th will be given a $0.32 dividend. This represents a $1.28 annualized dividend and a dividend yield of 0.7%. The ex-dividend date of this dividend is Friday, September 26th. Danaher’s dividend payout ratio (DPR) is presently 27.23%.

Insider Activity at Danaher

In other news, Director Teri List sold 2,778 shares of the business’s stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $211.06, for a total transaction of $586,324.68. Following the sale, the director directly owned 20,751 shares of the company’s stock, valued at $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 11.10% of the company’s stock.

Institutional Trading of Danaher

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Danaher by 1.3% in the second quarter. Vanguard Group Inc. now owns 60,769,587 shares of the conglomerate’s stock worth $12,004,424,000 after purchasing an additional 788,499 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock worth $4,016,404,000 after buying an additional 612,154 shares during the period. Geode Capital Management LLC raised its position in Danaher by 0.6% during the 2nd quarter. Geode Capital Management LLC now owns 13,726,194 shares of the conglomerate’s stock worth $2,697,800,000 after buying an additional 81,670 shares during the last quarter. Norges Bank acquired a new stake in Danaher during the 2nd quarter valued at approximately $1,979,503,000. Finally, Bank of New York Mellon Corp lifted its stake in Danaher by 2.3% during the 1st quarter. Bank of New York Mellon Corp now owns 8,783,485 shares of the conglomerate’s stock valued at $1,800,614,000 after acquiring an additional 194,466 shares during the period. Institutional investors and hedge funds own 79.05% of the company’s stock.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.